The distributors – one regional and one national – will sell directly to patients, according to a release. Electromed said it expects minimal impact to fiscal 2020 revenues and expenses from the agreement.
New Prague, Minn.-based Electromed’s SmartVest is designed to use high frequency chest wall oscillation to clear lungs of excess secretions and reduce the risk of respiratory infections and hospitalizations for non-cystic fibrosis bronchiectasis patients.
“The homecare distribution channel expands physician and patient access to the SmartVest in certain areas of the United States and broadens exposure of the SmartVest brand,” president & CEO Kathleen Skarvan said in prepared remarks. “The direct-to-patient and provider channel will continue to be our primary focus for homecare revenue. Expanding sales channels through homecare distribution will complement our direct sales efforts and support growth initiatives to expand the underserved bronchiectasis market and acceptance of high frequency chest wall oscillation therapy with SmartVest.”